| Title |
Effectiveness of gefitinib in combination with methotrexate in the treatment of ectopic pregnancy
|
|---|---|
| Published in |
International Journal of Women's Health, July 2015
|
| DOI | 10.2147/ijwh.s55556 |
| Pubmed ID | |
| Authors |
Perrine Capmas, Hervé Fernandez |
| Abstract |
Medical management for ectopic pregnancy is subject to substantial variations with different protocols and various routes of administration. Regardless the protocol used, methotrexate is currently the medical treatment of choice for ectopic pregnancy. The risk of a rescue surgery is a main concern. Recently, some studies suggested combining gefitinib and methotrexate to improve medical treatment and to decrease the need for reinjection and for additional surgery. Gefitinib is an orally administered EGF receptor-tyrosine kinase inhibitor. For tubal ectopic pregnancy, median recovery time was shorter after combination treatment with gefitinib and methotrexate. Toxicity reported with combination treatment was acneiform rash in 67% of cases and diarrhea in 42%. They were always transient and are known side effects of gefitinib previously described in lung cancer. These preliminary results are very promising but need to be explored further before wide distribution. For ectopic pregnancy, combining treatment seems to be interesting but results of the first randomized trial have to be evaluated first. For other indications, such as non-tubal ectopic pregnancy or choriocarcinoma, randomized studies are needed before wide use of the combination in current practice. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 17 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 2 | 12% |
| Student > Master | 2 | 12% |
| Student > Ph. D. Student | 2 | 12% |
| Lecturer | 1 | 6% |
| Student > Doctoral Student | 1 | 6% |
| Other | 3 | 18% |
| Unknown | 6 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 29% |
| Nursing and Health Professions | 1 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 6% |
| Social Sciences | 1 | 6% |
| Physics and Astronomy | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 8 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 July 2015.
All research outputs
#20,823,121
of 25,584,565 outputs
Outputs from International Journal of Women's Health
#671
of 850 outputs
Outputs of similar age
#203,137
of 277,879 outputs
Outputs of similar age from International Journal of Women's Health
#14
of 15 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 850 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.1. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,879 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.